Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.

摘要: Glycoprotein (GP) IIb/IIIa receptor antagonists compose a subcategory of antiplatelet medications that reduce thrombus formation through the blockade key binding sites needed to stabilize forming platelet aggregate. The GP receptors have been identified as therapeutic target in reducing occurrence platelet-dependent formation. One advantage is because platelet-specific, inhibition this does not affect adhesion. This may contribute hemostasis without leading ischemic damage. platelet-specific pharmacological activity has allowed for its broad use clinical settings. Based on trials, extensively studied and used patients with acute coronary syndrome or during percutaneous interventions. goal present article provide detailed review chemical structures mode action currently Food Drug Administration-approved United States.